[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Filana Therapeutics Inc (FLNA)

Filana Therapeutics Inc (FLNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,979
  • Shares Outstanding, K 48,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -90,970 K
  • EBIT $ -82 M
  • EBITDA $ -81 M
  • 60-Month Beta -0.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.10

Options Overview Details

View History
  • Implied Volatility 102.03% (-1.79%)
  • Historical Volatility 61.81%
  • IV Percentile 5%
  • IV Rank 10.90%
  • IV High 440.51% on 03/30/26
  • IV Low 60.63% on 05/26/26
  • Expected Move (DTE 16) 0.1275 (8.56%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 243
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 29,714
  • Open Int (30-Day) 31,542
  • Expected Range 1.3625 to 1.6175

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1600 +29.31%
on 05/13/26
1.6000 -6.25%
on 06/01/26
-0.0100 (-0.66%)
since 05/01/26
3-Month
1.1600 +29.31%
on 05/13/26
2.4900 -39.76%
on 03/10/26
-0.8200 (-35.34%)
since 03/02/26
52-Week
1.1600 +29.31%
on 05/13/26
4.9800 -69.88%
on 10/16/25
-0.6300 (-29.58%)
since 06/02/25

Most Recent Stories

More News
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies...

FLNA : 1.4700 (-1.34%)
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies...

FLNA : 1.4700 (-1.34%)
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent manner Results confirm and extend previously...

FLNA : 1.4700 (-1.34%)
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused...

FLNA : 1.4700 (-1.34%)
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading...

FLNA : 1.4700 (-1.34%)
SAVA : 2.38 (+12.26%)

Business Summary

Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 1.6733
2nd Resistance Point 1.6367
1st Resistance Point 1.5633
Last Price 1.4700
1st Support Level 1.4533
2nd Support Level 1.4167
3rd Support Level 1.3433

See More

52-Week High 4.9800
Fibonacci 61.8% 3.5208
Fibonacci 50% 3.0700
Fibonacci 38.2% 2.6192
Last Price 1.4700
52-Week Low 1.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.